Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; HepQuant LLC, Greenwood Village, Colorado.
Transl Res. 2021 Jul;233:5-15. doi: 10.1016/j.trsl.2020.12.010. Epub 2021 Jan 2.
The HepQuant SHUNT test quantifies liver function and blood flow using systemic and portal clearances of cholate. The test can identify the risk of well-compensated patients to develop complications of cirrhosis. To confirm the reliability of a single HepQuant SHUNT test we defined its within-individual reproducibility. Healthy subjects (n = 16), 16 with nonalcoholic steatohepatitis (NASH), and 16 with chronic hepatitis C virus (HCV) underwent 3 HepQuant SHUNT tests on 3 separate days within 30 days. The test involves simultaneous administration of 20 mg 13C-cholate IV and 40 mg d4-cholate PO, and subsequent collection of 3 mL blood samples at 5, 20, 45, 60, and 90 minutes. Clearances are expressed as systemic and portal hepatic filtration rate. Portal-systemic shunting (SHUNT), a disease severity index (DSI), and an estimate of DSI (STAT) are calculated from the clearances. Reproducibility was determined by the intraclass correlation coefficient (ICC > 0.70) and Bland-Altman analysis. Equal numbers of NASH and HCV patients had either early (F0-F2) or advanced (F3/F4) stages of fibrosis. All F3/F4 subjects were clinically compensated. The intraclass correlation coefficient (ICC) for DSI was 0.94 (0.90-0.96 95% confidence interval) indicating excellent reproducibility. The other test parameters had ICCs ranging from 0.74 (SHUNT) to 0.90 (STAT). In Bland-Altman analysis, the mean of differences between measurements of DSI was 0.13 with standard deviation 2.12. The excellent reproducibility of the HepQuant SHUNT test, particularly DSI, supports the use this minimally invasive, blood-based test as a reliable test of liver function and physiology.
HepQuant SHUNT 测试使用胆酸盐的全身和门脉清除率来量化肝功能和血流。该测试可以识别代偿良好的患者发生肝硬化并发症的风险。为了确认单次 HepQuant SHUNT 测试的可靠性,我们定义了其个体内的可重复性。16 名健康受试者、16 名非酒精性脂肪性肝炎(NASH)患者和 16 名慢性丙型肝炎病毒(HCV)患者在 30 天内的 3 个不同日子内进行了 3 次 HepQuant SHUNT 测试。该测试包括同时静脉注射 20 mg 13C-胆酸盐和口服 40 mg d4-胆酸盐,并在 5、20、45、60 和 90 分钟后采集 3 毫升血样。清除率表示为全身和门脉肝滤过率。从清除率计算门体分流(SHUNT)、疾病严重程度指数(DSI)和 DSI 的估计值(STAT)。通过组内相关系数(ICC>0.70)和 Bland-Altman 分析确定可重复性。NASH 和 HCV 患者的数量相等,分别具有早期(F0-F2)或晚期(F3/F4)纤维化阶段。所有 F3/F4 受试者均有临床代偿。DSI 的组内相关系数(ICC)为 0.94(0.90-0.96,95%置信区间),表明具有极好的可重复性。其他测试参数的 ICC 范围为 0.74(SHUNT)至 0.90(STAT)。在 Bland-Altman 分析中,DSI 测量值之间的差异平均值为 0.13,标准差为 2.12。HepQuant SHUNT 测试的极好可重复性,特别是 DSI,支持将这种微创、基于血液的测试用作肝功能和生理学的可靠测试。